Protagonist Therapeutics, Inc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Protagonist Therapeutics, Inc (PTGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.11% for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-04.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2021-08-04
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-06-30 was 1.11%, a 164.29% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 0.97%, a 32.64% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-06-30 was 0.42%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.44%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 1.79%, a 13.29% increase from fiscal 2015.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 1.58%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2021-06-30 | 1.11% 10-Q · filed 2021-08-04 | 1.11% 10-Q · filed 2021-08-04 | ||
| 2021-03-31 | 0.97% 10-Q · filed 2021-05-04 | |||
| 2020-06-30 | 0.42% 10-Q · filed 2021-08-04 | 1.44% 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | 1.44% 10-Q · filed 2021-05-04 | |||
| 2016-12-31 | 1.79% 10-K · filed 2017-03-07 | |||
| 2016-09-30 | 1.38% 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | 1.38% 10-Q · filed 2016-09-15 | |||
| 2015-12-31 | 1.58% 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |